Literature DB >> 35263769

Interventional Treatment Options in Children with Extracranial Vascular Malformations.

Vanessa F Schmidt1, Martin Olivieri2, Beate Häberle3, Max Masthoff4, Sinan Deniz1, Peter B Sporns5,6, Walter A Wohlgemuth7, Moritz Wildgruber1.   

Abstract

Extracranial vascular malformations vary greatly and belong to the complex field of orphan diseases and can involve all segments of the vascular tree: arteries, capillaries, and veins, and similarly the lymphatic system. The classification according to the International Society for the Study of Vascular Anomalies (ISSVA) represents an important guidance for selecting appropriate therapy. Although many of the principles of endovascular treatment, including image-guided sclerotherapy and embolization, are similar in adult and pediatric practice, there are some distinct differences regarding the treatment of vascular malformations of children. Thus, it is crucial to involve longer-term plan about managing these chronic diseases and their impact on a growing child. This review provides a detailed overview over the clinical presentation of venous, lymphatic, and arteriovenous malformations in children and emphasizes the specifics of their interventional treatment options, including distinct pediatric dose limitations and procedure-related side effects. Thieme. All rights reserved.

Entities:  

Mesh:

Year:  2022        PMID: 35263769     DOI: 10.1055/a-1728-5686

Source DB:  PubMed          Journal:  Hamostaseologie        ISSN: 0720-9355            Impact factor:   1.778


  1 in total

1.  Clinical Outcome and Quality of Life of Multimodal Treatment of Extracranial Arteriovenous Malformations: The APOLLON Study Protocol.

Authors:  Vanessa F Schmidt; Max Masthoff; Veronika Vielsmeier; Caroline T Seebauer; Özlem Cangir; Lutz Meyer; Antje Mükke; Werner Lang; Axel Schmid; Peter B Sporns; Richard Brill; Walter A Wohlgemuth; Natascha Platz Batista da Silva; Max Seidensticker; Regina Schinner; Julia Küppers; Beate Häberle; Frank Haubner; Jens Ricke; Martin Zenker; Melanie A Kimm; Moritz Wildgruber
Journal:  Cardiovasc Intervent Radiol       Date:  2022-10-19       Impact factor: 2.797

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.